{
  "id": 220,
  "text": "The radiotherapy subgroup took the decision - again in agreement with a large amount of radiation oncology reviewers of this guideline - to allocate IMRT with IGRT including simultaneous lymph node boosting to represent the “preferred treatment” for external beam radiotherapy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: The radiotherapy subgroup took the decision - again in agreement with a large amount of radiation oncology reviewers of this guideline - to allocate IMRT with IGRT including simultaneous lymph node boosting to represent the “preferred treatment” for external beam radiotherapy.\n\n<question>: ",
  "ChatGPT_response_0": "這種決定的益處在於同時應用淋巴結加速的IMRT與IGRT作為外部束放射治療的「首選治療」，可以有效提高治療的準確性和有效性。IMRT（調控照射放射治療）和IGRT（影像引導放射治療）技術結合，可以更精確地瞄準腫瘤，同時最大程度地保護周圍組織，減少副作用的發生。此外，同時進行淋巴結加速的放射治療可以提高局部控制率，改善患者的預後。\n\n然而，這樣的治療方法也面臨一些挑戰。首先，IMRT和IGRT技術較為複雜，需要高度訓練的專業人員進行操作和監控，增加了醫療團隊的工作量。其次，淋巴結加速的放射治療可能會增加治療的時間和成本。此外，對於某些特定的患者群體，這種治療方案的益處和風險需要進一步的研究和評估，以確保最佳的治療效果和安全性。",
  "query": "放射治療小組再次與大量放射腫瘤學評論者一致決定，將同時淋巴結加速的IMRT與IGRT分配為外部束放射治療的「首選治療」，你認為這種決定的益處和挑戰在哪裡？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 放射治療小組再次與大量放射腫瘤學評論者一致決定，將同時淋巴結加速的IMRT與IGRT分配為外部束放射治療的「首選治療」，你認為這種決定的益處和挑戰在哪裡？\n\n<reference text>: The radiotherapy subgroup took the decision - again in agreement with a large amount of radiation oncology reviewers of this guideline - to allocate IMRT with IGRT including simultaneous lymph node boosting to represent the “preferred treatment” for external beam radiotherapy.\n\n<reply>: ",
  "response": "這種決定的益處在於同時應用淋巴結加速的IMRT與IGRT作為外部束放射治療的「首選治療」，可以有效提高治療的準確性和有效性。IMRT（調控照射放射治療）和IGRT（影像引導放射治療）技術結合，可以更精確地瞄準腫瘤，同時最大程度地保護周圍組織，減少副作用的發生。此外，同時進行淋巴結加速的放射治療可以提高局部控制率，改善患者的預後。\n\n然而，這樣的治療方法也面臨一些挑戰。首先，IMRT和IGRT技術較為複雜，需要高度訓練的專業人員進行操作和監控，增加了醫療團隊的工作量。其次，淋巴結加速的放射治療可能會增加治療的時間和成本。此外，對於某些特定的患者群體，這種治療方案的益處和風險需要進一步的研究和評估，以確保最佳的治療效果和安全性。"
}